透析療法ネクスト　XXIV

出版社： 医学図書出版
著者：
発行日： 2018-05-15
分野： 臨床医学：内科  >  腎臓
ISBN： 9784865172584
電子書籍版： 2018-05-15
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,860 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,716 円(税込)

購入する

商品紹介

シリーズ第24弾！「エテルカルセチドSHPT治療の次なるステージへ」と題し、特集・座談会を収載しています。

目次

  • 座談会
    ■エテルカルセチドへの期待

    特集　エテルカルセチドSHPT治療の次なるステージへ
    ■1．SHPTの病態と治療の歴史
    　はじめに
    　1．SHPTの病態
    　2．SHPT治療の変遷
    　おわりに
    ■2．SHPT治療・国内外の相違について
    　はじめに
    　1．各国におけるPTH値の管理状況
    　2．シナカルセト塩酸塩の処方頻度、処方量
    　3．活性型ビタミンD製剤とシナカルセト塩酸塩の選択と併用
    　4．エテルカルセチド塩酸塩
    　5．副甲状腺摘出術に関する国際比較
    　6．ビタミンD不足の評価と補充療法
    　おわりに
    ■3．エテルカルセチドの非臨床試験成績と静注剤としての特長
    　はじめに
    　1．エテルカルセチドの開発の歴史
    　2．薬効薬理試験の成績
    　3．薬物動態試験の成績
    　4．Calcimimeticsの上部消化器症状について
    　おわりに
    ■4．エテルカルセチドの臨床試験成績
    　1)　エテルカルセチド国内第Ⅰ/Ⅱ相試験について　　横山啓太郎
    　　はじめに
    　　1．エテルカルセチド第Ⅰ/Ⅱ相試験・単回・反復投与試験
    　　2．エテルカルセチドの反復投与
    　　おわりに
    　2)　国内第Ⅲ相試験について　　重松　　隆，大矢　昌樹
    　　はじめに
    　　1．エテルカルセチド国内第Ⅲ相試験：長期投与試験が行われるまで
    　　2．エテルカルセチド国内第Ⅲ相試験：長期投与試験の方法
    　　3．エテルカルセチド国内第Ⅲ相試験：長期投与試験における投与方法
    　　4．エテルカルセチド国内第Ⅲ相試験：長期投与試験の結果
    　　おわりに
    　3)　海外成績について　　大井　克征，神田英一郎
    　　1．エテルカルセチドの概要
    　　2．海外の臨床成績
    　　まとめ
    ■5．当院における使用経験について
    　1） シナカルセト塩酸塩の効果的な投与方法ならびに
    　　　　エテルカルセチド塩酸塩に対する期待と課題
    　　　　─低Ca濃度透析液使用下の透析前後における
    　　　　　i-PTHの変動に与える両薬剤の影響─
    　　はじめに
    　　1．目的
    　　2．対象
    　　3．方法
    　　4．結果
    　　5．考察
    　　結論
    　2)　当院におけるエテルカルセチドの使用経験
    　　緒言
    　　1．対象
    　　2．方法
    　　3．統計解析
    　　4．結果
    　　考察
    ■6．SHPT治療と骨代謝
    　はじめに
    　1．CKD-MBDと骨代謝
    　2．SHPT治療の骨代謝への影響
    　おわりに
    ■7．SHPT治療と長期予後
    　はじめに
    　1．血清Ca濃度やリン濃度を下げる臨床的な意義は？
    　2．血清FGF23を低下させる臨床的意義は？
    　3．シナカルセトによる死亡抑制効果
    　4．エビデンスレベルの観点からの比較
    　5．ビタミンDと予後に関する日本からの最近のエビデンス
    　6．これからのSHPT治療に求めるエビデンス
    ■8．エテルカルセチドによるSHPT治療の期待と課題
    　はじめに
    　1．エテルカルセチドはアドヒアランスと消化器症状を本当に改善できるのか？
    　2．長期予後をどこまで明らかにできるか？
    　3．副甲状腺機能亢進症治療薬としてのカルシウム受容体作動薬の位置づけ
    　おわりに
    ■INDEX

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

座談会

P.8 掲載の参考文献
1) Geng Y, et al : ELife 5, e13662, 2016
PubMed
2) Leach K, et al : Cell Res 26 (5), 574-592, 2016
PubMed
3) Alexander ST, et al : Mol Pharmacol 88 (5), 853-865, 2015
PubMed
4) パーサビブ(R) 静注透析用 承認時評価資料, 小野薬品工業株式会社
 
5) Block JA, et al : JAMA 317 (2), 156-164, 2017
 
6) Ruat M, et al : Best Pract Res Clin Endocrinol Metab 27 (3), 429-442, 2013
PubMed
7) 福本和生, 他 : 透析会誌 43 (3), 309-315, 2010
 
8) Tominaga Y, et al : Curr Opin Nephrol Hypertens 5 (4), 336-341, 1996
PubMed
9) Imanishi Y, et al : Expert Opin Drug Discov 4 (7), 727-740, 2009
PubMed
10) Imanishi Y, et al : Calcif Tissue Int 89 (1), 29-35, 2011
PubMed
11) Stein GS, et al : Physiol Rev 76 (2), 593-629, 1996
PubMed
12) Dobnig H, et al : Endocrinology 138 (11), 4607-4612, 1997
PubMed
13) Caltabiano S, et al : Bone 56 (1), 154-162, 2013
PubMed
14) Fitzpatrick LA, et al : J Bone Miner Res 27 (2), 255-262, 2012
PubMed
15) Peacock M, et al : J Clin Endocrinol Metab 96 (1), E9-18, 2011
 
16) Abdelhadi M, et al : J Clin Endocrinol Metab 83 (11), 3845-3851, 1998
PubMed
17) Rudser KD, et al : J Am Soc Nephrol 18 (8), 2401-2407, 2007
PubMed
18) Goodman WG, et al : J Am Soc Nephrol 13 (4), 1017-1024, 2002
PubMed
19) Cunningham J, et al : Kidney Int 68 (4), 1793-1800, 2005
PubMed
20) Chertow GM, et al : N Engl J Med 367 (26), 2482-2494, 2012
PubMed
21) パーサビブ(R) 静注透析用 市販直後調査の結果報告. 小野薬品工業株式会社
 

特集 エテルカルセチドSHPT治療の次なるステージへ

P.16 掲載の参考文献
1) Bricker NS : On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". N Engl J Med 286 : 1093-1099, 1972
PubMed
2) Hasegawa H, Nagano N, Urakawa I, et al : Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78 : 975-980, 2010
PubMed
3) Brown EM : Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56 : 572-581, 1983
 
4) Brown AJ, Ritter CS, Finch JL, et al : Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats : role of dietary phosphate. Kidney Int 55 : 1284-1292, 1999
PubMed
5) Yano S, Sugimoto T, Tsukamoto T, et al : Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 58 : 1980-1986, 2000
PubMed
6) Cafiadillas S, Canalejo A, Santamaria R, et al : Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J Am Soc Nephrol 16 : 2190-2197, 2005
PubMed
7) Canaff L, Hendy GN : Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1, 25-dihy-droxyvitamin D. J Biol Chem 277 : 30337-30350, 2002
 
8) Ritter CS, Finch JL, Slatopolsky EA, et al : Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 60 : 1737-1744, 2001
PubMed
9) Mizobuchi M, Ritter CS, Krits I, et al : Calcium-Sensing receptor expression is regulated by glial cells missing-2 in human parathyroid cells. J Bone Miner Res 24 : 1173-1179, 2009
 
10) Mizobuchi M, Hatamura I, Ogata H, et al : Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 15 : 2579-2587, 2004
PubMed
11) Ritter C, Miller B, Coyne DW, et al : Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. Kidney Int 92 : 1217-1222, 2017
PubMed
12) Breitwieser GE : Pharmacoperones and the calcium sensing receptor : exogenous and endogenous regulators. Pharmacol Res 83 : 30-37, 2014
PubMed
13) Fukuda N, Tanaka H, Tominaga Y, et al : Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92 : 1436-1443, 1993
PubMed
14) Patel SR, Ke HQ, Vanholder R, et al : Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 96 : 50-59, 1995
PubMed
15) Kremer R, Bolivar I, Goltzman D, et al : Influence of calcium and 1, 25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 125 : 935-941, 1989
PubMed
16) Tokumoto M, Tsuruya K, Fukuda K, et al : Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 62 : 1196-1207, 2002
 
17) Slatopolsky E, Caglar S, Pennell JP, et al : On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 50 : 492-499, 1971
PubMed
18) Slatopolsky E, Finch J, Denda M, et al : Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97 : 2534-2540, 1996
PubMed
19) Slatopolsky E : The intact nephron hypothesis : the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int Suppl 79 : S3-8, 2011
PubMed
20) Van Buren PN, Lewis JB, Dwyer JP, et al : The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients : Results From Prespecified Analyses of a Randomized Clinical Trial. Am J Kidney Dis 66 : 479-488, 2015
PubMed
21) Naveh-Many T, Rahamimov R, Livni N, et al : Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96 : 1786-1793, 1995
PubMed
22) Sela-Brown A, Silver J, Brewer G, et al : Identification of AUF1 as a parathyroid hormone mRNA 3'-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem 275 : 7424-7429, 2000
PubMed
23) Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al : The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117 : 4003-4008, 2007
PubMed
24) Canalejo R, Canalejo A, Martinez-Moreno JM, et al : FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 21 : 1125-1135, 2010
PubMed
25) Galitzer H, Ben-Dov IZ, Silver J, et al : Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77 : 211-218, 2010
PubMed
26) Kumata C, Mizobuchi M, Ogata H, et al : Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol 31 : 230-238, 2010
PubMed
27) Komaba H, Goto S, Fujii H, et al : Depressedexpression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77 : 232-238, 2010
 
28) Roman-Garcia P, Carrillo-Lopez N, Naves-Diaz M, et al : Dual-specificity phosphatases are implicated in severe hyperplasia and lack of response to FGF23 of uremic parathyroid glands from rats. Endocrinology 153 : 1627-1637, 2012
PubMed
29) Olauson H, Lindberg K, Amin R, et al : Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet 9 : e1003975, 2013
PubMed
30) Volovelsky O, Cohen G, Kenig A, et al : Phosphorylation of Ribosomal Protein S6 Mediates Mammalian Target of Rapamycin Complex 1-Induced Parathyroid Cell Proliferation in Secondary Hyperparathyroidism. J Am Soc Nephrol 27 : 1091-1101, 2016
PubMed
31) Shilo V, Silver J, Naveh-Many T : Micro-RNAs in the parathyroid : anew portal in understanding secondary hyperparathyroidism. Curr Opin Nephrol Hypertens 25 : 271-277, 2016
 
32) Zerwekh JE, Brumbaugh PF, Haussler DH, et al : 1α-hydroxyvitamin D3. An analog of vitamin D which apparently acts by metabolism to 1α, 25-dihydroxyvitamin D3. Biochemistry 13 : 4097-4102, 1974
 
33) Nishii Y, Abe J, Mori T, et al : The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. Contrib Nephrol 91 : 123-128, 1991
PubMed
34) Akiba T, Marumo F, Owada A, et al : Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 32 : 238-246, 1998
PubMed
35) Fukagawa M, Yumita S, Akizawa T, et al : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008
PubMed
36) Fukagawa M, Yokoyama K, Shigematsu T, et al : A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32 : 1723-1730, 2017
 
37) Nordal KP, Dahl E : Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 67 : 929-936, 1988
PubMed
38) Andress DL, Norris KC, Coburn JW, et al : Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321 : 274-279, 1989
PubMed
39) Hayashi M, Tsuchiya Y, Itaya Y, et al : Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis : a randomized prospective multicentre trial. Nephrol Dial Transplant 19 : 2067-2073, 2004
 
40) Sprague SM, Llach F, Amdahl M, et al : Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63 : 1483-1490, 2003
PubMed
41) Ketteler M, Block GA, Evenepoel P, et al : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update : what's changed and why it matters. Kidney Int 92 : 26-36, 2017
PubMed
42) Block GA, Martin KJ, de Francisco AL, et al : Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 : 1516-1525, 2004
PubMed
43) Komaba H, Nakanishi S, Fujimori A, et al : Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 5 : 2305-2314, 2010
 
44) Urefia-Torres PA, Floege J, Hawley CM, et al : Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant 28 : 146-152, 2013
 
45) EVOLVE Trial Investigators, Chertow GM, Block GA, et al : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
46) Akizawa T, Kurita N, Mizobuchi M, et al : PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 6 : 19612, 2016
PubMed
47) Messa P, Macario F, Yaqoob M, et al : The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 : 36-45, 2008
PubMed
48) Fukagawa M, Yokoyama K, Koiwa F, et al : Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17 : 247-288, 2013
PubMed
49) Komaba H, Taniguchi M, Wada A, et al : Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88 : 350-359, 2015
PubMed
50) Hsu YH, Yu HY, Chen HJ, et al : The Risk of Peripheral Arterial Disease after Parathyroidectomy in Patients with End-Stage Renal Disease. PLoS One 11 : e0156863, 2016
PubMed
51) Ma TL, Chang RY, Chen HJ, et al : Risk of Acute Coronary Syndrome after Parathyroidectomy in Patients with End-Stage Renal Disease : A Population-Based Cohort Study in Taiwan. Nephrology (Carlton) 23 : 139-147, 2018
PubMed
P.27 掲載の参考文献
1) Goodkin DA, Bragg-Gresham JL, Koenig KG, et al : Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States : the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14 : 3270-3277, 2003
PubMed
2) Ledebo I, Lameire N, Charra B, et al : Improving the outcome of dialysis-opinion vs scientific evidence. Report on the Dialysis Opinion Symposium at the ERA-EDTA Congress, 6September 1999, Madrid. Nephrol Dial Transplant 15 : 1310-1316, 2000
 
3) Mactier R, Davies S, Dudley C, et al : Summary of the 5th edition of the Renal Association Clinical Practice Guidelines (2009-2012). Nephron Clin Pract 118 : c27-70, 2011
PubMed
4) National Kidney Foundation : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 : S1-201, 2003
PubMed
5) Jindal K, Chan CT, Deziel C, et al : Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 17 : S1-27, 2006
PubMed
6) Elder G, Faull R, Branley P, et al : The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton) 11 : S230-261, 2006
PubMed
7) 日本透析医学会編 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
8) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl : S1-130, 2009
PubMed
9) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group : KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKDMBD). Kidney Int Suppl 7 : 1-59, 2017
 
10) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
11) Tentori F, Blayney MJ, Albert JM, et al : Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH : the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52 : 519-530, 2008
PubMed
12) Taniguchi M, Fukagawa M, Fujii N, et al : Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 17 : 221-228, 2013
 
13) Akizawa T, Kurita N, Mizobuchi M, et al : PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep : 19612, 2016
PubMed
14) Tentori F, Wang M, Bieber BA, et al : Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis : the DOPPS study. Clin J Am Soc Nephrol 10 : 98-109, 2015
PubMed
15) Kalantar-Zadeh K, Miller JE, Kovesdy CP, et al : Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. J Bone Miner Res 25 : 2724-2734, 2010
PubMed
16) Saran R, Bragg-Gresham JL, Rayner HC, et al : Nonadherence in hemodialysis : associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 64 : 254-262, 2003
PubMed
17) Komaba H, Fukagawa M : Cinacalcet and Clinical Outcomes in Dialysis. Semin Dial 28 : 594-603, 2015
PubMed
18) St Peter WL, Li Q, Liu J, et al : Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 4 : 354-360, 2009
 
19) Vervloet M, Bencova V, Malberti F, et al : "Real-World" use of cinacalcet for managing SHPT in different European countries : analysis of data from the ECHO observational study. Clin Nephrol 74 : 198-208, 2010
PubMed
20) Komaba H, Kakuta T, Fukagawa M : Management of secondary hyperparathyroidism : how and why? Clin Exp Nephrol 21 : S37-45, 2017
 
21) Messa P, Macario F, Yaqoob M, et al : The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 : 36-45, 2008
PubMed
22) Fishbane S, Shapiro WB, Corry DB, et al : Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone : the ACHIEVE study results. Clin J Am Soc Nephrol 3 : 1718-1725, 2008
PubMed
23) Wetmore JB, Gurevich K, Sprague S, et al : A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). J Clin Am Soc Nephrol 10 : 1031-1040, 2015
 
24) Akizawa T, Kido R, Fukagawa M, et al : Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism : associations with changing practice patterns. Clin J Am Soc Nephrol 6 : 2280-2288, 2011
PubMed
25) Fukagawa M, Fukuma S, Onishi Y, et al : Prescription patterns and mineral metabolism abnormalities in the cinacalcet era : results from the MBD-5D study. Clin J Am Soc Nephrol 7 : 1473-1480, 2012
PubMed
26) Rudser KD, de Boer IH, Dooley A, et al : Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18 : 2401-2407, 2007
PubMed
27) Tominaga Y, Kakuta T, Yasunaga C, et al : Evaluation of Parathyroidectomy for Secondary and Tertiary Hyperparathyroidism by the Parathyroid Surgeons' Society of Japan. Ther Apher Dial 20 : 6-11, 2016
PubMed
28) Wetmore JB, Liu J, Do TP, et al : Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy. Nephrol Dial Transplant 31 : 103-111, 2016
PubMed
29) Komaba H, Taniguchi M, Wada A, et al : Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88 : 350-359, 2015
PubMed
30) Komaba H, Nakamura M, Fukagawa M : Resurgence of parathyroidectomy : evidence and outcomes. Curr Opin Nephrol Hypertens 26 : 243-249, 2017
PubMed
31) Ishani A, Liu J, Wetmore JB, et al : Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 10 : 90-97, 2015
 
32) Agarwal R, Georgianos PI : Con : Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 31 : 706-713, 2016
PubMed
33) Sprague SM, Crawford PW, Melnick JZ, et al : Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol 44 : 316-325, 2016
PubMed
P.37 掲載の参考文献
1) Walter S, Baruch A, Dong J, et al : Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 346 : 229-240, 2013
PubMed
2) 井上敦人, 原田一恒 : 世界初の非経口calcimimetics ; エテルカルセチド塩酸塩の発見と研究開発. Clin Calcium 27 : 537-545, 2017
 
3) 原田一恒, 井上敦人, 山内昭典, 他 : 世界初の静注CaSR作動薬エテルカルセチド塩酸塩 (パーサビブ(R) 静注透析用) の薬理学的特性と臨床効果. 日薬理誌 150 : 98-113, 2017
Medical*Online
4) Harada K : ETELCALCETIDE (ONO-5163, AMG 416), an intravenously available allosteric modulator of the calcium sensing receptor, effectively controls parathyroid hormone levels in a rat chronic renal insufficiency model with secondary hyperparathyroidism. Nephrol Dial Transplant 31 : i246-258, 2016
 
5) Alexander ST, Hunter T, Walter S, et al : Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action. Mol Pharmacol 88 : 853-865, 2015
PubMed
6) Walter S, Baruch A, A｝exander ST, et al : Comparison of AMG 416 and cinacalcet in rodent models of uremia. BMC Nephrol 15 : 81, 2014
 
7) Li X, Yu L, Asuncion F, et al : Etelcalcetide (AMG 416), apeptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. Bone 105 : 163-172, 2017
 
8) 小野薬品工業株式会社 : エテルカルセチド塩酸塩 承認時評価資料 (社内資料).
 
9) Chen P, Narayanan A, Wu B, et al : Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. Clin Pharmacokinet 57 : 71-85, 2018
PubMed
10) Leach K, Wen A, Cook AE, et al : Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. Endocrinology 154 : 1105-1116, 2013
PubMed
11) Subramanian R, Zhu X, Kerr SJ, et al : Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide). Drug Metab Dispos 44 : 1319-1331, 2016
 
12) Subramanian R, Zhu X, Hock MB, et al : Pharmacokinetics, Biotransformation, and Excretion of [14C] Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis. Clin Pharmacokinet 56 : 179-192, 2017
PubMed
13) Fielden MR, Dean C Jr, Black K, et al : Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism. Int J Toxicol 35 : 294-308, 2016
PubMed
14) Yokoyama K, Fukagawa M, Shigematsu T, et al : A Single-and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. KI Reports 2 : 634-644, 2017
PubMed
15) Fukagawa M, Yokoyama K, Shigematsu T, et al : A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32 : 1723-1730, 2017
PubMed
16) Shigematsu T, Fukagawa M, Yokoyama K, et al : Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 22 : 426-436, 2018
PubMed
17) Yokoyama K, Fukagawa M, Shigematsu T, et al : A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin Nephrol 88 : 68-78, 2017
PubMed
18) Gincherman Y, Moloney K, McKee C, et al : Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int 14 : 68-72, 2010
PubMed
19) 協和発酵キリン株式会社 : シナカルセト塩酸塩審査報告書.
 
20) 永野伸郎, 筒井貴朗 : カルシウム感知受容体を標的とした薬剤の薬理学的特性-シナカルセト塩酸塩のallosteric modulatorとしての特長-. Clin Calcium 26 : 839-850, 2016
 
21) 谷口正智 : Calcimimeticの副作用とさまざまな臓器への効果. Clin Calcium 18 : 45-50, 2008
 
22) 近藤雄一朗, 他 : ミニブタを用いたシナカルセト塩酸塩の迷走神経活動電位に与える影響の検討. 腎と透析 82 : 455-459, 2017
Medical*Online
23) 協和発酵キリン株式会社 : シナカルセト塩酸塩承認時評価資料.
 
24) Block GA, Bushinsky DA, Cheng S, et al : Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism : A Randomized Clinical Trial. JAMA 317 : 156-164, 2017
PubMed
25) Ketteler M : Etelcalcetide : A new treatment option in the management of SHPT in haemodialysis patients, Treatment of SHPT with the injectable etelcalcetide. 54th ERA-EDTA congress. 4th June, 2017
 
26) 濱野直人, 深川雅史 : 二次性副甲状腺機能亢進症の非経口calcimimeticsによる治療. Clin Calcium 27 : 567-572, 2017
 
27) Hamano N, Komaba H, Fukagawa M : Etelcalcetide for the treatment of secondary hyperparathyroidism. Expert Opin Pharmacother 18 : 529-534, 2017
PubMed
28) Cozzolino M, Galassi A, Conte F, et al : Treatment of secondary hyperparathyroidism : the clinical utility of etelcalcetide. Ther Clin Risk Manag 13 : 679-689, 2017
PubMed
29) Morrow T : Parsabiv Could Be Pricey Addi tion In Care for CKD, ESRD Patients. Manag Care 26 : 33-34, 2017
 
P.48 掲載の参考文献
1) Moe S, Drueke T, Cunningham J, et al : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006
PubMed
2) Raggi P, Kleerekoper M : Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 3 : 836-843, 2008
PubMed
3) Goodman WG, Goldin J, Kuizon BD, et al : Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 : 1478-1483, 2000
 
4) Blacher J, Guerin AP, Pannier B, et al : Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 : 938-942, 2001
PubMed
5) Jean G, Chazot C, Charra B : 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism : effect on bone markers. Clin Nephrol 68 : 63-64, 2007
 
6) Sterrett JR, Strom J, Stummvoll HK, et al : Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68 : 10-17, 2007
PubMed
7) Moe SM, Chertow GM, Coburn JW, et al : Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 : 760-771, 2005
 
8) Messa P, Macario F, Yaqoob M, et al : The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 : 36-45, 2008
PubMed
9) Yokoyama K, Fukagawa M, Shigematsu T, et al : A Single-and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. Kidney Int Rep 2 : 634-644, 2017
PubMed
10) Martin KJ, Pickthorn K, Huang S, et al : AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int 85 : 191-197, 2014
 
11) Subramanian R, Zhu X, Kerr SJ, et al : Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide). Drug Metab Dispos 44 : 1319-1331, 2016
 
12) Ohashi N, Uematsu T, Nagashima S, et al : The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 57 : 726-734, 2004
PubMed
P.58 掲載の参考文献
1) Chen P, Olsson Gisleskog P, Perez-Ruixo JJ, et al : Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. CPT Pharmacometrics Syst Pharmacol 5 : 484-494, 2016
PubMed
2) Yokoyama K, Fukagawa M, Shigematsu T, et al : A Single-and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. Kidney Int Rep 2 : 634-644, 2017
PubMed
3) Yokoyama K, Fukagawa M, Shigematsu T, et al : A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients, Clin Nephrol 88 : 68-78, 2017
PubMed
4) Shigematsu T, Fukagawa M, Yokoyama K, et al : Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 22 : 426-436, 2018
PubMed
5) Fukagawa M, Yokoyama K, Shigematsu T, et al : A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32 : 1723-1730, 2017
PubMed
6) Block GA, Bushinsky DA, Cheng S, et al : Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism : A Randomized Clinical Trial. JAMA 317 : 156-164, 2017
PubMed
7) Fukagawa M, Yokoyama K, Koiwa F, et al : Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17 : 247-288, 2013
PubMed
8) Ketteler M, Block GA, Evenepoel P, et al : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update : what's changed and why it matters. Kidney Int 92 : 26-36, 2017
PubMed
P.66 掲載の参考文献
1) Subramanian R, Zhu X, Kerr SJ, et al : Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide). Drug Metab Dispos 44 : 1319-1331, 2016
 
2) Subramania R, Zhu X, Hock MB, et al : Pharmacokinetics, Biotransformation, and Excretion of [14C] Etelcalcetid (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis. Clin Pharmacokinet 56 : 179-192, 2017
 
3) Moe SM, Thadhani R : What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? Curr Opin Nephrol Hypertens 22 : 651-655, 2013
PubMed
4) EVOLVE Trial Investigators, Chertow GM, Block GA, et al : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
5) Walter S, Baruch A, Dong J, et al : Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patinets. J Pharmacol Exp Ther 346 : 229-240, 2013
 
6) Martin KJ, Bell G, Pickthorn K, et al : Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant 29 : 385-392, 2014
PubMed
7) Martin KJ, Pickthron K, Huang S, et al : AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int 85 : 191-197, 2014
 
8) Bell G, Huang S, Martin KJ, et al : A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin 31 : 943-952, 2015
PubMed
9) Bushinsky DA, Block GA, Martin KJ, et al : Treatment of Secondary Hyperparathyroidism : Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor. Am J Nephrol 42 : 379-388, 2015
PubMed
10) Block GA, Bushinsky DA, Cunningham J, et al : Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism : Two Randomized Clinical Trials. JAMA 317 : 146-155, 2017
PubMed
11) Block GA, Bushinsky DA, Cheng S, et al : Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism : A Randomized Clinical Trial. JAMA 317 : 156-164, 2017
PubMed
12) Cozzolino M, Galassi A, Conte F, et al : Treatment of secondary hyperparathyroidism : the clinical utility of etelcalcetide. Ther Clin Risk Manag 13 : 679-689, 2017
PubMed
P.77 掲載の参考文献
1) 伊達敏行, 重松隆 : 特集 カルシウム・リン調節薬の使い分け. 透析液の適正カルシウム濃度-各種薬剤との関連-. 臨牀透析 19 : 71-77, 2003
 
2) 伊達敏行, 小林肇, 川下誉晃, 他 : 臨床HDとHDFにおけるCaのバランススタディー. 腎と透析 55 : S135-137, 2003
 
3) 伊達敏行 : 透析液の種類と選択-私の選択- (1) 医師に訊く. 透析フロンティア 15 : 5-7, 2005
 
4) 伊達敏行 : Cinacalcetの副作用とその対策. 透析療法ネクスト IX : 123-132, 2009
 
5) Subramanian R, Zhu X, Hock MB, et al : Pharmacokinetics, Biotransformation, and Excretion of [14C] Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis. Clin Pharrnacokinet 156 : 179-192, 2017
 
6) Subramanian R, Zhu X, Kerr SJ, et al : Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide). Drug Metab Dispos 44 : 1319-1331, 2016
 
7) Edson KZ, Wu BM, Iyer A, et al : Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing. Kidney International Reports 1 : 24-33, 2016
PubMed
8) Chen P, Melhem M, Xiao J, et al : Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol 55 : 620-628, 2015
PubMed
9) Date T, Kawashita Y, Matsuzaki M, et al : The administration of cinacalcet hydrochloride just before a haemodialysis session suppresses the transient rise in intact parathyroid hormone induced by a low-calcium dialysate : when should cinacalcet hydrochloride be administered? NDT Plus 1 : 463-464, 2008
PubMed
10) 伊達敏行, 川下誉晃, 重松隆 : 新しい副甲状腺インターベンションの治療戦略 : PECIT (ペキット : エタノール+calcitriol注入療法) の有用性. 透析会誌 37 : 50-52, 2004
 
11) 伊達敏行, 川下誉晃, 佐竹伸由 : 慢性血液透析症例におけるColestimideのリン吸着剤としての有用性. 透析会誌 34 : 111-117, 2001
 
12) Date T, Shigematsu T, Kawashita Y, et al : Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dialysis Transplant 18 : S90-93, 2003
 
13) 伊達敏行 : ADWIC (Aggressive iv VD3 with Cinacalcet) 療法によるMedicalPTXの可能性. 奈良県医師会透析部会誌 18 : 11-18, 2013
 
14) 福本和生, 野口智永, 酉家佐吉子, 他 : シナカルセト塩酸塩の上部消化管合併症の機序. 透析会誌 43 : 309-315, 2010
 
15) 春山和佳, 川田剛央, 紹慶洋治, 他 : シナカルセト塩酸塩の嘔吐誘発作用に対するドンペリドンの予防効果-マーモセットおよびラットを用いた基礎検討-. 腎と透析 70 : 301-306, 2011
Medical*Online
16) 近藤雄一朗, 加藤正巳, 細見篤史, 他 : ミニブタを用いたシナカルセト塩酸塩の迷走神経活動電位に与える影響の検討. 腎と透析 82 : 455-460, 2017
Medical*Online
17) 伊達敏行 : 透析患者の栄養障害とカルニチン補充療法-ビタミンD3, 亜鉛, およびカルニチン補充の臨床経験-. 透析療法ネクスト XVII : 33-44, 2014
 
18) 伊達敏行, 重松隆林恭子, 他 : 静注ビタミンD3パルス療法の腎性貧血改善効果とその機序に関する臨床的検討. 臨牀透析 27 : 743-748, 2011
 
19) Bell G, Huang S, Martin KJ, et al : A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin 31 : 943-952, 2015
PubMed
20) Walter S, Baruch A, Dong J, et al : Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 346 : 229-240, 2013
PubMed
21) Shen J, Xiao J, Pickthorn K, et al : A pharmacokinetic/pharmacodynamics model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects. J Clin Pharmacol 54 : 1125-1133, 2014
PubMed
22) Martin KJ, Bell G, Pickthorn K, et al : Velcalcetide (AMG 416), anovel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant 29 : 385-392, 2014
 
23) Martin KJ, Pickthorn K, Huang S, et al : AMG 416 (velcalcetide) is a ovel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. kidney Int 85 : 191-197, 2014
 
24) Hamano N, Komaba H, Fukagawa M, et al : Etelcalcetide for the treatment of secondary hyperparathyroidism. Expert Opin Pharmacother 18 : 529-534, 2017
PubMed
25) 原田一恒, 井上敦人, 山内昭典, 他 : 世界初の静注CaSR作動薬エテルカルセチド塩酸塩 (パーサビブ(R) 静注透析用) の薬理学的特性と臨床効果. 日薬理誌 150 : 98-113, 2017
Medical*Online
26) 井上敦人, 原田一恒 : 世界初の非経口calcimimetics ; エテルカルセチド塩酸塩の発見と研究開発. CLINICAL CALCIUM 27 : 67-75, 2017
 
27) Yokoyama K, Fukagawa M, Shigematsu T, et al : A 12-week dose-escalating of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathuroidism in Japanese hemodialysis patients. Clin Nephrol 88 : 68-78, 2017
PubMed
28) Yokoyama K, Fukagawa M, Shigematsu T, et al : A Single-and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanease Hemodyalysis Patients With Secondary Hyperparathyroidism. Kidney Int Rep 2 : 634-644, 2017
 
29) Fukagawa M, Yokoyama K, Shigematsu T, et al : A phase 3, multicenter, randomized, double-blind, placebo-controled, parallelgroup study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32 : 1723-1730, 2017
 
30) Block GA, Bushinsky DA, Cunningham J, et al : Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism : Two Randomized Clinical Trials. JAMA 317 : 146-155, 2017
PubMed
31) Block GA, Bushinsky DA, Cheng S, et al : Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving-Hemodialysis With Secondary Hyperparathyroidism : A Randomized Clinical Trials. JAMA 317 : 156-164, 2017
PubMed
32) パーサビブ(R) 透析静注用 (2.5mg/5mg/10mg, 小野薬品工業株式会社), 医薬品インタビューフォーム. パーサビブ(R) の薬物動態. 薬力学的特徴 Q&A 2-7, 2017
 
33) 伊達敏行, 川下誉晃, 小林肇 : 慢性血液透析症例における血中Ca分画の検討. Nephrology Frontier (増刊号) : 27-30, 2007
 
34) 伊達敏行 : 血液透析前後における血中Ca分画の変動に関する検討-アセテートフリー透析液とアセテート含有透析液の比較検討-. Nephrology Frontier (増刊号) : 71-74, 2008
 
35) 伊達敏行, 松崎美香, 山本忠司, 他 : 血管石灰化の進行を抑制するための望ましい透析液Ca濃度に関する検討. 透析会誌 45 : 1019-1020, 2012
 
P.83 掲載の参考文献
1) 日本透析医学会編 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
2) Shigematsu T, Akizawa T, Uchida E, et al : Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 29 : 230-236, 2009
PubMed
3) Akizawa T, Kurita N, Mizobuchi M, et al : PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 6 : 19612, 2016
PubMed
4) Raggi P, Chertow GM, Torres PU, et al : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011
PubMed
5) Moe SM, Chertow GM, Parfrey PS, et al : Cinacalcet, fibroblast growth factor-23, and cardiovascular dis-ease in hemodialysis : The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation 132 : 27-39, 2015
 
6) Moe SM, Abdalla S, Chertow GM, et al : Effects of cinacalcet on fracture events in patients receiving hemodialysis : The EVOLVE Trial. J Am Soc Nephrol 26 : 1466-1475, 2015
 
7) Shigematsu T, Akizawa T, Uchida E, et al : Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 29 : 230-236, 2009
PubMed
8) Fukagawa M, Komaba H, Onishi Y, et al : Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan : baseline data from the MBD-5D. Am J Nephrol 33 : 427-437, 2011
PubMed
9) Fishbane S, Shapiro WB, Corry DB, et al : Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone : the ACHIEVE study results. Clin J Am Soc Nephrol 3 : 1718-1725, 2008
PubMed
10) Raggi P, Chertow GM, Torres PU, et al : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011
PubMed
11) EVOLVE Trial Investigators, Chertow GM, Block GA, et al : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
12) Fukagawa M, Yokoyama K, Shigematsu T, et al : A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32 : 1723-1730, 2017
PubMed
13) Block GA, Bushinsky DA, Cheng S, et al : Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism : arandomized clinical trial. JAMA 317 : 156-164, 2017
 
14) Yamada S, Inaba M, Kurajoh M, et al : Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease : independence from renal dysfunction. Clin Endocrinol (Oxf) 69 : 189-196, 2008
PubMed
15) Shidara K, Inaba M, Okuno S, et al : Serum levels of TRACP5b, a new bone resorption marker unaffected by renal dysfunction, as auseful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 82 : 278-287, 2008
 
P.89 掲載の参考文献
1) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113 : S1-130, 2009
PubMed
2) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group : KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 7 : 1-59, 2017
 
3) Nickolas TL, Stein EM, Dworakowski E, et al : Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28 : 1811-1820, 2013
PubMed
4) Fan Y, Hanai JI, Le PT, et al : Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. Cell Metab 25 : 661-672, 2017
PubMed
5) 日本透析医学会編 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
6) Kir S, Komaba H, Garcia AP, et al : PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer. Cell Metab 23 : 315-323, 2016
PubMed
7) Atsumi K, Kushida K, Yamazaki K, et al : Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33 : 287-293, 1999
PubMed
8) Cannata-Andia JB, Roman-Garcia P, Hruska K : The connections between vascular calcification and bone health. Nephrol Dial Transplant 26 : 3429-3436, 2011
PubMed
9) Iimori S, Mori Y, Akita W, et al : Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study. Nephrol Dial Transplant 27 : 345-351, 2012
PubMed
10) Yenchek RH, Ix JH, Shlipak MG, et al : Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7 : 1130-1136, 2012
PubMed
11) Naylor KL, Garg AX, Zou G, et al : Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 10 : 646-653, 2015
PubMed
12) West SL, Lok CE, Langsetmo L, et al : Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res 30 : 913-919, 2015
PubMed
13) Yajima A, Ogawa Y, Takahashi HE, et al : Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 42 : 729-738, 2003
PubMed
14) Yajima A, Inaba M, Ogawa Y, et al : Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism. Nephrol Dial Transplant 22 : 1645-1657, 2007
PubMed
15) Yano S, Sugimoto T, Tsukamoto T, et al : Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism : possible usefulness of preoperative determinanation of parathyroid hormone level for prediction of bone regain. Horm Metab Res 35 : 259-264, 2003
 
16) Yano S, Suzuki K, Sumi M, et al : Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism. J Bone Miner Metab 28 : 49-54, 2010
PubMed
17) Floege J, Kubo Y, Floege A, et al : The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis : The EVOLVE Trial. Clin J Am Soc Nephrol 10 : 800-807, 2015
PubMed
18) Ishimura E, Okuno S, Tsuboniwa N, et al : Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 76 : 259-265, 2011
 
19) Tsuruta Y, Okano K, Kikuchi K, et al : Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 17 : 120-126, 2013
 
20) EVOLVE Trial Investigators, Chertow GM, Block GA, et al : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
21) Moe SM, Abdalla S, Chertow GM, et al : Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis : The EVOLVE Trial. J Am Soc Nephrol 26 : 1466-1475, 2015
 
22) Tanaka M, Yoshida K, Fukuma S, et al : Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia : Results from the MBD-5D Study. PLoS One 11 : e0164865, 2016
PubMed
23) Block GA, Bushinsky DA, Cunningham J, et al : Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism : Two Randomized Clinical Trials. JAMA 317 : 146-155, 2017
PubMed
24) Block GA, Bushinsky DA, Cheng S, et al : Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism : A Randomized Clinical Trial. JAMA 317 : 156-164, 2017
PubMed
25) Fukagawa M, Yokoyama K, Shigematsu T, et al : A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32 : 1723-1730, 2017
PubMed
26) Li X, Yu L, Asuncion F, et al : Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. Bone 105 : 163-172, 2017
 
P.97 掲載の参考文献
1) Hamano T, Matsui I, Mikami S, et al : Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 21 : 1998-2007, 2010
PubMed
2) Raggi P, Chertow GM, Torres PU, et al : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011
PubMed
3) Floege J, Kubo Y, Floege A, et al : The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis : The EVOLVE Trial. Clin J Am Soc Nephrol 10 : 800-807, 2015
PubMed
4) Chang TI, Abdalla S, London GM, et al : The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. J Hum Hypertens 30 : 204-209, 2016
 
5) Moe SM, Chertow GM, Parfrey PS, et al : Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis : The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation 132 : 27-39, 2015
PubMed
6) Silswal N, Touchberry CD, Daniel DR, et al : FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J physiol Endocrinol Metab 307 : E426-436, 2014
PubMed
7) Choi SR, Lim JH, Kim MY, et al : Cinacalcet improves endothelial dysfunction and cardiac hypertrophy in patients on hemodialysis with secondary hyperparathyroidism. Nephron Clin Pract 122 : 1-8, 2012
PubMed
8) EVOLVE Trial Investigators, Chertow GM, Block GA, et al : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
9) Pasch A, Block GA, Bachtler M, et al : Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. Clin J Am Soc Nephrol 12 : 315-322, 2017
PubMed
10) Wheeler DC, London GM, Parfrey PS, et al : Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis : the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J Am Heart Assoc 3 : e001363, 2014
 
11) Block GA, Zaun D, Smits G, et al : Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 78 : 578-589, 2010
 
12) Akizawa T, Kurita N, Mizobuchi M, et al : PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 6 : 19612, 2016
PubMed
13) Parfrey PS, Drueke TB, Block GA, et al : The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis : The Evaluation of Cinacalcet HCI Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol 10 : 791-799, 2015
 
14) Obi Y, Hamano T, Wada A, et al : Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients : a Nationwide Cohort Study using Coarsened Exact Matching. Sci Rep 7 : 41170, 2017
PubMed
15) Tanaka S, Ninomiya T, Taniguchi M, et al : Comparison of oral versus intravenous vitamin D receptor activator in reducing infection-related mortality in hemodialysis patients : the Q-Cohort Study. Nephrol Dial Transplant 31 : 1152-1160, 2016
 
P.100 掲載の参考文献
1) Komaba H, Kakuta T, Fukagawa M : Management of secondary hyperparathyroidism : how and why? Clin Exp Nephrol 21 : S37-45, 2017
 
2) Fukagawa M, Yumita S, Akizawa T, et al : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phohphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008
PubMed
3) Komaba H, Nakanishi S, Fujimori A, et al : Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 5 : 2305-2314, 2010
 
4) Akizawa T, Kurita N, Mizobuchi M, et al : PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidiam. Sci Rep 6 : 19612, 2016
PubMed
5) Fukagawa M, Yokoyama K, Shigematsu T, et al : A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant 32 : 1723-1730, 2017
PubMed
6) Block GA, Bushinsky DA, Cheng S, et al : Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism : ARandomized Clinical Trial. JAMA 317 : 156-164, 2017
 
7) 福本和生, 野口智永, 西家佐吉子, 他 : シナカルセト塩酸塩の上部消化管合併症の機序. 透析会誌 43 : 309-315, 2010
 
8) The EVOLVE Trial Investigators : Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
9) Hamano N, Komaba H, Fukagawa M : Etelcalcetide for the treatment of secondary hyperparathyroidism. Expert Op Pharmacotherap 18 : 529-534, 2017
 
10) Ketteler M, Block GA, Evenepoel P, et al : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update : what's changed and why it matters. Kidney Int 92 : 26-36, 2017
PubMed
11) Komaba H, Nakamura M, Fukagawa M : Resurgence of parathyroidectomy : evidence and outcomes. Curr Opin Nephrol Hypertens 26 : 243-249, 2017
PubMed

書評

最近チェックした商品履歴

Loading...